Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Antibodies targeting IL-17A or its receptor, IL-17RA, are approved to treat psoriasis and are being evaluated for other autoimmune conditions. Conversely, IL-17 signaling is critical for immunity to opportunistic mucosal infections caused by the commensal fungus Candida albicans, as mice and humans lacking the IL-17R experience chronic mucosal candidiasis. IL-17A, IL-17F, and IL-17AF bind the IL-17RA-IL-17RC heterodimeric complex and deliver qualitatively similar signals through the adaptor Act1. Here, we used a mouse model of acute oropharyngeal candidiasis to assess the impact of blocking IL-17 family cytokines compared with specific IL-17 cytokine gene knockout mice. Anti-IL-17A antibodies, which neutralize IL-17A and IL-17AF, caused elevated oral fungal loads, whereas anti-IL-17AF and anti-IL-17F antibodies did not. Notably, there was a cooperative effect of blocking IL-17A, IL-17AF, and IL-17F together. Termination of anti-IL-17A treatment was associated with rapid C. albicans clearance. IL-17F-deficient mice were fully resistant to oropharyngeal candidiasis, consistent with antibody blockade. However, IL-17A-deficient mice had lower fungal burdens than anti-IL-17A-treated mice. Act1-deficient mice were much more susceptible to oropharyngeal candidiasis than anti-IL-17A antibody-treated mice, yet anti-IL-17A and anti-IL-17RA treatment caused equivalent susceptibilities. Based on microarray analyses of the oral mucosa during infection, only a limited number of genes were associated with oropharyngeal candidiasis susceptibility. In sum, we conclude that IL-17A is the main cytokine mediator of immunity in murine oropharyngeal candidiasis, but a cooperative relationship among IL-17A, IL-17AF, and IL-17F exists in vivo. Susceptibility displays the following hierarchy: IL-17RA- or Act1-deficiency > anti-IL-17A + anti-IL-17F antibodies > anti-IL-17A or anti-IL-17RA antibodies > IL-17A deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells
Acosta-Rodriguez, E. V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A., Sallusto, F., & Napolitani, G. (2007) · Nature Immunology · doi:10.1038/ni1467 · Cited by 1,828 · cited 1×
“Adult humans harbor a potent adaptive CD4Th17 response toward this fungus [71, 72], and generation of an adaptive Th17 response has been similarly shown in mouse Candida rechallenge models [47, 73].”
BackgroundThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585 · cited 2×
“The IL-17 cytokine family has unique structural and functional features [28, 29] (Fig.”
BackgroundSelf-citationTargeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414 · cited 1×
“Drugs targeting IL-17A and IL-17RA have shown efficacy for autoimmune psoriasis, psoriatic arthritis, and ankylosing spondylitis [1, 59].”
BackgroundFunctional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
IL-25 Induces IL-4, IL-5, and IL-13 and Th2-Associated Pathologies In Vivo
Fort, M. M., Cheung, J., Yen, D., Li, J., Zurawski, S. M., Lo, S., Menon, S., Clifford, T., Hunte, B., Lesley, R., et al. (2001) · Immunity · doi:10.1016/s1074-7613(01)00243-6 · Cited by 1,203
Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome
Milner, J. D., Brenchley, J. M., Laurence, A., Freeman, A. F., Hill, B. J., Elias, K. M., Kanno, Y., Spalding, C., Elloumi, H. Z., Paulson, M. L., et al. (2008) · Nature · doi:10.1038/nature06764 · Cited by 1,157
Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis
Iliev, I. D., Funari, V. A., Taylor, K. D., Nguyen, Q., Reyes, C. N., Strom, S. P., Brown, J., Becker, C. A., Fleshner, P. R., Dubinsky, M., et al. (2012) · Science · doi:10.1126/science.1221789 · Cited by 1,073
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056 · cited 2×
“Functional synergy between IL-17A and IL-17F has similarly been demonstrated in response to Staphylococcus aureus, another infection associated with IL-17RA or IL-17F [11, 60].”
BackgroundConti, H. R., Shen, F., Nayyar, N., Stocum, E., Sun, J. N., Lindemann, M. J., Ho, A. W., Hai, J. H., Yu, J. J., Jung, J. W., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081463 · Cited by 1,024 · cited 4×
“This time point was selected as this is when the major IL-17-driven immune response to acute OPC reaches its peak [23].”
BackgroundInfluentialIshigame, H., Kakuta, S., Nagai, T., Kadoki, M., Nambu, A., Komiyama, Y., Fujikado, N., Tanahashi, Y., Akitsu, A., Kotaki, H., et al. (2009) · Immunity · doi:10.1016/j.immuni.2008.11.009 · Cited by 1,004 · cited 2×
“IL-17A, IL-17F, and Act1 mice were described [44, 45].”
BackgroundPathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β
Zielinski, C. E., Mele, F., Aschenbrenner, D., Jarrossay, D., Ronchi, F., Gattorno, M., Monticelli, S., Lanzavecchia, A., & Sallusto, F. (2012) · Nature · doi:10.1038/nature10957 · Cited by 919
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Self-citationRequirement of Interleukin‐17A for Systemic Anti– Candida albicans Host Defense in Mice
Huang, W., Na, L., Fidel, P. L., & Schwarzenberger, P. (2004) · The Journal of Infectious Diseases · doi:10.1086/422329 · Cited by 859 · cited 1×
“IL-17 is also implicated in systemic candidiasis in mice, although the release of IFN-g from Th1 cells also contributes to the activation of neutrophils and macrophages in this setting [26, 27].”
BackgroundImpairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations
Okada, S., Markle, J. G., Deenick, E. K., Mele, F., Averbuch, D., Lagos, M., Alzahrani, M., Al-Muhsen, S., Halwani, R., Ma, C. S., et al. (2015) · Science · doi:10.1126/science.aaa4282 · Cited by 413
Gladiator, A., Wangler, N., Trautwein-Weidner, K., & LeibundGut-Landmann, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202924 · Cited by 382
Ruddy, M. J., Wong, G. C., Liu, X. K., Yamamoto, H., Kasayama, S., Kirkwood, K. L., & Gaffen, S. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308809200 · Cited by 364 · cited 1×
“supernatants was measured as a readout for IL-17 activity [52, 53].”
Self-citationStarnes, T., Broxmeyer, H. E., Robertson, M. J., & Hromas, R. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.2.642 · Cited by 331 · cited 7×
“IL-17A, IL-17F, or IL-17AF (R&D Systems) was used at 100 ng/ml, and TNF-a (PeproTech, Rocky Hill, NJ, USA) was used at 1 ng/ml. cLN cells in AIM Vmedia (Gibco, Thermo Fisher Scientific) were treated 62 mg/ml aCD3 (clone 145-2C11; BD Biosciences, Fisher Scientific, Pittsburgh, PA, USA) or heat-killed C. albicans (2 3 1…”
BackgroundInfluentialIdentification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells
Wright, J. F., Guo, Y., Quazi, A., Luxenberg, D. P., Bennett, F., Ross, J. F., Qiu, Y., Whitters, M. J., Tomkinson, K. N., Dunussi-Joannopoulos, K., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700499200 · Cited by 319 · cited 1×
“This receptor is also used by a heterodimer of IL-17A bound to IL-17F through a covalent disulfide linkage (IL-17AF) [30–34].”
BackgroundBoisson, B., Wang, C., Pedergnana, V., Wu, L., Cypowyj, S., Rybojad, M., Belkadi, A., Picard, C., Abel, L., Fieschi, C., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.09.002 · Cited by 293 · cited 2×
“Mutations in IL17RA, IL17RC, IL17F, the adaptor ACT1, and the transcription factor RORC have been identified in human CMC [10–13].”
BackgroundShen, F., Ruddy, M. J., Plamondon, P., & Gaffen, S. L. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0904490 · Cited by 268 · cited 1×
“murine stromal cell line [24, 51].”
Self-citationMiossec, P. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10816 · Cited by 264
Oral-resident natural Th17 cells and γδ T cells control opportunistic Candida albicans infections
Conti, H. R., Peterson, A. C., Brane, L., Huppler, A. R., Hernández-Santos, N., Whibley, N., Garg, A. V., Simpson-Abelson, M. R., Gibson, G. A., Mamo, A. J., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130877 · Cited by 254
Self-citationKagami, S., Rizzo, H. L., Kurtz, S. E., Miller, L. S., & Blauvelt, A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001153 · Cited by 216
Structural basis of receptor sharing by interleukin 17 cytokines
Ely, L. K., Fischer, S., & Garcia, K. C. (2009) · Nature Immunology · doi:10.1038/ni.1813 · Cited by 195 · cited 1×
“This receptor is also used by a heterodimer of IL-17A bound to IL-17F through a covalent disulfide linkage (IL-17AF) [30–34].”
BackgroundInterleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis
Ferreira, M. C., Whibley, N., Mamo, A. J., Siebenlist, U., Chan, Y. R., & Gaffen, S. L. (2014) · Infection and Immunity · doi:10.1128/iai.01389-13 · Cited by 72 · cited 3×
“Therefore, the increased fungal loads in anti-IL-17A antibody-treated mice were unlikely a result of decreased expression of Lcn2 or Cxcl5, which is consistent with published data [54, 58].”
BackgroundMethodResult
Cited by
IL-17 and IL-17-producing cells in protection versus pathology
Mills, K. H. G. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00746-9 · Cited by 1,000
IL-17 receptor–based signaling and implications for disease
Li, X., Bechara, R., Zhao, J., McGeachy, M. J., & Gaffen, S. L. (2019) · Nature Immunology · doi:10.1038/s41590-019-0514-y · Cited by 548
Self-citationThe IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
Brembilla, N. C., Senra, L., & Boehncke, W.-H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01682 · Cited by 475
The IL-17 family in diseases: from bench to bedside
Huangfu, L., Li, R., Huang, Y., & Wang, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01620-3 · Cited by 452
d'Enfert, C., Kaune, A.-K., Alaban, L.-R., Chakraborty, S., Cole, N., Delavy, M., Kosmala, D., Marsaux, B., Fróis-Martins, R., Morelli, M., et al. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa060 · Cited by 347
Metadata
- Authors
- Whibley, N., Tritto, E., Traggiai, E., Kolbinger, F., Moulin, P., Brees, D., Coleman, B. M., Mamo, A. J., Garg, A. V., Jaycox, J. R., Siebenlist, U., Kammüller, M., & Gaffen, S. L.
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-06-01
- Volume
- 99
- Issue
- 6
- Pages
- 1153-1164
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2228244209
- Cited by
- 65
- References
- 26
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.